Table 2 Regression analysis testing for interactions between treatment and the subtyping dimensions to predict APC in MRI measures
From: Differential response to donepezil in MRI subtypes of mild cognitive impairment
F | R2 | B | p | |
|---|---|---|---|---|
APC hippocampal volume | 1.1 | 0.04 | - | 0.340 |
Treatment | − 2.0 | 0.660 | ||
BV/CSF index | 0.1 | 0.810 | ||
Hippocampus-to-cortex ratio | − 17.7 | 0.740 | ||
Age | − 0.03 | 0.710 | ||
MRI field strength | 0.2 | 0.820 | ||
BV/CSF index by treatment | 0.01 | 0.930 | ||
Hippocampus-to-cortex by treatment | 25.2 | 0.490 | ||
APC ventricles volume | 4.4 | 0.1 | - | < 0.001 |
Treatment | 8.9 | 0.138 | ||
BV/CSF index | − 0.1 | 0.710 | ||
Hippocampus-to-cortex ratio | 61.8 | 0.042 | ||
Age | − 0.04 | 0.660 | ||
MRI field strength | 0.4 | 0.750 | ||
BV/CSF index by treatment | − 0.1 | 0.310 | ||
Hippocampus-to-cortex by treatment | − 101.8 | 0.041 | ||
APC total grey matter volume | 2.1 | 0.1 | - | 0.050 |
Treatment | 2.5 | 0.450 | ||
BV/CSF index | 0.04 | 0.014 | ||
Hippocampus-to-cortex ratio | 4.6 | 0.270 | ||
Age | − 0.1 | 0.910 | ||
MRI field strength | 1.4 | 0.051 | ||
BV/CSF index by treatment | 0.1 | 0.130 | ||
Hippocampus-to-cortex by treatment | − 27.7 | 0.310 | ||
APC AD signature cortical thickness | 2.5 | 0.1 | - | 0.030 |
Treatment | − 2.2 | 0.175 | ||
BV/CSF index | 0.01 | 0.808 | ||
Hippocampus-to-cortex ratio | − 71.7 | 0.230 | ||
Age | − 0.1 | 0.340 | ||
MRI field strength | 1.7 | 0.100 | ||
BV/CSF index by treatment | 0.1 | < 0.001 | ||
Hippocampus-to-cortex by treatment | 16.4 | 0.020 |